These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 22991415)
1. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Wermke M; Schmidt A; Middeke JM; Sockel K; von Bonin M; Schönefeldt C; Mair S; Plodeck V; Laniado M; Weiss G; Schetelig J; Ehninger G; Theurl I; Bornhäuser M; Platzbecker U Clin Cancer Res; 2012 Dec; 18(23):6460-8. PubMed ID: 22991415 [TBL] [Abstract][Full Text] [Related]
2. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730 [TBL] [Abstract][Full Text] [Related]
3. Measurement of liver iron concentration by superconducting quantum interference device biomagnetic liver susceptometry validates serum ferritin as prognostic parameter for allogeneic stem cell transplantation. Jacobi N; Herich L Eur J Haematol; 2016 Oct; 97(4):336-41. PubMed ID: 26800433 [TBL] [Abstract][Full Text] [Related]
4. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Wermke M; Eckoldt J; Götze KS; Klein SA; Bug G; de Wreede LC; Kramer M; Stölzel F; von Bonin M; Schetelig J; Laniado M; Plodeck V; Hofmann WK; Ehninger G; Bornhäuser M; Wolf D; Theurl I; Platzbecker U Lancet Haematol; 2018 May; 5(5):e201-e210. PubMed ID: 29628397 [TBL] [Abstract][Full Text] [Related]
5. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
6. Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome. Tachibana T; Takasaki H; Tanaka M; Maruta A; Hyo R; Ishigatsubo Y; Kanamori H Bone Marrow Transplant; 2011 Jan; 46(1):150-1. PubMed ID: 20383206 [No Abstract] [Full Text] [Related]
7. Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation. Virtanen JM; Itälä-Remes MA; Remes KJ; Vahlberg T; Saunavaara JP; Sinisalo M; Parkkola RK Eur J Haematol; 2013 Jul; 91(1):85-93. PubMed ID: 23586843 [TBL] [Abstract][Full Text] [Related]
8. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372 [TBL] [Abstract][Full Text] [Related]
9. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463 [TBL] [Abstract][Full Text] [Related]
10. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131 [TBL] [Abstract][Full Text] [Related]
11. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Majhail NS; DeFor T; Lazarus HM; Burns LJ Biol Blood Marrow Transplant; 2008 Jul; 14(7):790-4. PubMed ID: 18541198 [TBL] [Abstract][Full Text] [Related]
12. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Armand P; Kim HT; Rhodes J; Sainvil MM; Cutler C; Ho VT; Koreth J; Alyea EP; Hearsey D; Neufeld EJ; Fleming MD; Steen H; Anderson D; Kwong RY; Soiffer RJ; Antin JH Biol Blood Marrow Transplant; 2011 Jun; 17(6):852-60. PubMed ID: 20854920 [TBL] [Abstract][Full Text] [Related]
13. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Majhail NS; Lazarus HM; Burns LJ Biol Blood Marrow Transplant; 2010 Jun; 16(6):832-7. PubMed ID: 20079863 [TBL] [Abstract][Full Text] [Related]
14. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634 [TBL] [Abstract][Full Text] [Related]
15. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Trottier BJ; Burns LJ; DeFor TE; Cooley S; Majhail NS Blood; 2013 Aug; 122(9):1678-84. PubMed ID: 23777771 [TBL] [Abstract][Full Text] [Related]
16. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Scott BL; Storer BE; Greene JE; Hackman RC; Appelbaum FR; Deeg HJ Biol Blood Marrow Transplant; 2007 Mar; 13(3):345-54. PubMed ID: 17317588 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in allo-SCT of elderly patients with AML. Krauter J; Wagner K; Stadler M; Dammann E; Zucknick M; Eder M; Buchholz S; Mischak-Weissinger E; Hertenstein B; Ganser A Bone Marrow Transplant; 2011 Apr; 46(4):545-51. PubMed ID: 20548341 [TBL] [Abstract][Full Text] [Related]
18. Iron overload in allogeneic hematopoietic stem cell transplant recipients. Ali S; Pimentel JD; Munoz J; Shah V; McKinnon R; Divine G; Janakiraman N Arch Pathol Lab Med; 2012 May; 136(5):532-8. PubMed ID: 22540302 [TBL] [Abstract][Full Text] [Related]
19. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679 [TBL] [Abstract][Full Text] [Related]
20. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]